The Medicines Patent Pool has signed agreements with 27 generics manufacturers to supply oral COVID-19 medication molnupiravir to 105 low- and-middle-income countries (LMICs). The sublicense agreements are the result of the voluntary licensing agreement signed by the MPP and Merck Sharp & Dohme in October last year to facilitate affordable global access to molnupiravir.
Molnupiravir received emergency use authorization from the US Food and Drug Administration in December to treat mild-to-moderate COVID-19 in adults deemed to be at high risk for progression to severe...
